

[Supplementary Table Legend](#)

Supplementary Table 1: Therapy regimens


[Supplementary Figure Legend](#)

Supplementary Figure 1: Comparison of EQ-5D-5L response levels, split by health domain between AIH and PBC

Supplementary Table 1: Therapy regimens

Therapy	n	%	Median dose (range) (mg)
Prednisolone monotherapy	90	9.1%	7.3 (0.5-50)
Prednisolone combination	409	41.3%	5.0 (0.2-60)
Budesonide monotherapy	13	1.3%	6 (1.5-9.0)
Budesonide combination	34	3.4%	3 (0.4-9.0)
Azathioprine monotherapy	299	30.2%	100 (25-250)
Dose/weight (mg/kg)			1.1 (0.2-2.6)
Azathioprine combination	282	28.5%	100 (25-250)
Dose/weight (mg/kg)			1.2 (0.2-2.8)
6-Mercaptopurine monotherapy	22	2.2%	50 (25-100)
6-Mercaptopurine combination	26	2.6%	50 (12-150)
Mycophenolate mofetil/ mycophenolic acid monotherapy	50	5.1%	1000 (500 – 3000)
Mycophenolate mofetil/ mycophenolic acid combination	116	11.7%	1000 (200 – 3000)
Tacrolimus monotherapy	3	0.3%	1.5 (1.0-2.0)
Tacrolimus combination	38	3.8%	2 (0.5-9.0)
Cyclosporine monotherapy	1	0.1%	75 (NA)
Cyclosporine combination	5	0.5%	150 (50-300)

AIH



PBC

